glp-1 asa guidelines 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists aGLP-1 receptor agonists & anesthesia:

Maintain metabolic health.*

These medications have been shown to be beneficial in treating Type 2 diabetes, and several medications in this class have also been permitted for chronic weight management as well as cardiovascular risk reduction

Natriuretic Effect by Exendin-4, But Not the DPP-4 Inhibitor Alogliptin, is Mediated via the GLP-1 Receptor and Preserved in Obese Type 2 Diabetic Mice

WHY IT WORKS Multi-dimensional formula addresses the facial changes that occur when using GLP-1 agonists Formula works in 4D to improve the appearance of facial skin deflation, loose, sagging, crepey skin texture, dehydration, and deep wrinkles Proprietary XOSM technology boosts formula performance Improves the appearance of skin firmness, density and skin texture quality Deeply nourishes and hydrates, plumping the skin Protects and nourishes the skins barrier HOW TO USE To get the best results, VOL.U.LIFT should be used twice dailyin the morning and at nightas part of a complete skincare routine

A novel cardiometabolic therapeutic prospect Cardiometabolic diseases as diabetes mellitus, heart disease, overweight, obesity, hypertension, hyperlipidemia and its multiple macro and microvascular complications (ischemic cardiomyopathy, stroke, chronic kidney disease, retinopathy, peripheral neuropathy, etc.) are conditions closely related to each other and constitute at present time the leading cause of morbility, disability and death in the world [28]